Triplebar's Hyper-Throughput screening platform acts as a 'microprocessor for biology,' integrating hardware, software, biology and biochemistry to miniaturize and accelerate evolution. Triplebar and its commercial partners use the platform to develop biological systems for manufacturing low-cost, low-footprint animal proteins to replace traditional animal sources, improving the performance of animal cell lines for cellular meat products, and discovering novel therapeutic biologic drug candidates for addressing major human health challenges.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/30/23 | $20,000,000 |
Essential Capital iSelect Fund Stray Dog Capital Synthesis Capital  The Production Board | undisclosed |
